


Date: December 1, 2006

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.



Kim Blum
Name (Print)

Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	OHARA et al.)	Examiner:	Unassigned
)		
Application No.:	10/594,707)	Group Art Unit:	Unassigned
)		
Filed:	September 28, 2006)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-100)	Customer No.:	33432

For: GENE ENCODING A GUANINE NUCLEOTIDE EXCHANGE FACTOR
AND THE GENE PRODUCT THEREOF

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 1, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO/SB/08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application,

Information Disclosure Statement
U.S. Patent Application No. 10/594,707


and that the documents cited in the attached Form PTO/SB/08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-100
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO/SB/08 w/11 Documents



(Use as many sheets as necessary)

Application Number	10/594,707
Filing Date	September 28, 2006
First Named Inventor	OHARA et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	3190-100

Sheet 1 of 2

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 00/12711 A1	03-09-2000	Incyte Pharmaceuticals Inc.		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/594,707
				Filing Date	September 28, 2006
				First Named Inventor	OHARA et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	3190-100

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Preliminary Report on Patentability and Written Opinion for PCT/JP/2005/005918 dated October 26, 2006	
		HART et al., Cellular Transformation and Guanine Nucleotide Exchange Activity Are Catalyzed by a Common Domain on the <i>dbf</i> Oncogene Product," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269, No. 1, January 7, 1994, pp. 62-65.	
		BI et al., "Autoinhibition Mechanism of Proto-Dbl," MOLECULAR AND CELLULAR BIOLOGY, Vol. 21, No. 5, March 2001, pp. 1463-1474.	
		KATZAV et al., "VAV, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells," THE EMBO JOURNAL, Vol. 8, No. 8, 1989, pp. 2283-2290	
		COSTELLO et al., "The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-κB pathways," PROC. NATL. ACAD. SCI. USA, Vol. 96, March 1999, pp. 3035-3040.	
		HORII et al., "A novel oncogene, <i>ost</i> , encodes a guanine nucleotide exchange factor that potentially links Rho and Rac signaling pathways," THE EMBO JOURNAL, Vol. 13, No. 20, 1994, pp. 4776-4786	
		TOKSOZ et al., "Novel human oncogene LBC detected by transfection with distinct homology regions to signal transduction products," ONCOGENE, No. 9, 1994, pp. 621-628.	
		O'BRIEN et al., "Skeletal muscle deformity and neuronal disorder in Trio exchange factor-deficient mouse embryos," PNAS, Vol. 97, No. 22, October 24, 2000, pp. 12074-12078.	
		PENZES et al., "Distinct Roles for the Two Rho GDP/GTP Exchange Factor Domains of Kalirin in Regulation of Neurite Growth and Neuronal Morphology," THE JOURNAL OF NEUROSCIENCE, Vol. 21(21), November 1, 2001, pp. 8426-8434.	
		OHARA et al., "Construction and Characterization of Human Brain cDNA Libraries Suitable for Analysis of cDNA Clones Encoding Relatively Large Proteins," DNA RESEARCH, 4, 1997, pp. 53-59.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.